Breast Cancer Genes: When the Sequence Is Not Enough

In most cases, prostate cancer is a treatable disease. Typically slow growing tumors that occur in men at a median age of 70 years are often treated effectively by interfering with androgen hormone signaling. But in 10 percent of cases, prostate cancers metastasize, become resistant to androgen deprivation therapy, and turn lethal. Kathleen Kelly, Ph.D., Chief of CCR’s Cell and Cancer Biology Branch, has a long-standing interest in understanding the transformation from normal prostate cells into primary cancer and then into metastatic disease. Led by a desire to identify the earliest origins of prostate cancer, Kelly turned to a model system that allows her to study the cells that give rise to the disease as well as trace its metastatic spread. Read the full story »


Letting Sleeping Micrometastases Lie

Setting the Sun on Skin Cancer

Interferon-γ has been found to promote UV-induced melanoma in a mouse model

alt text

Hitting the Target

Researchers have identified a possible target for treating the most aggressive form of lymphoma.

alt text

Patent Pool Goes Global

CCR-developed HIV drug darunavir is the first patent licensed to the Medicines Patent Pool.

alt text

The Frontiers of Thymic Malignancy

The first International Conference on Thymic Malignancies at the NIH provided a forum to better manage this rare disease.

alt text

A Look at Rare Diseases, from Molecules to Patients

Workshop on Xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy examines diseases of DNA repair, cancer, and premature aging.

alt text

Test Before You Treat

CCR researcher Frank Gonzalez, Ph.D., is recognized for the development of a life-saving diagnostic test to identify cancer patients that may experience 5-fluorouracil toxicity.

alt text

Recent CCR Awards:

View the new 2011 CCR awards.


alt text

Staff News at CCR

Staff announcements at CCR.


alt text

In Conversation:

Research Fellow Ram Savan, Ph.D.